Indian pharmaceutical company Strides Arcolab has entered
into a licensing agreement with US-based Gilead Sciences to manufacture and
distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in
In a BSE filing, Strides Arcolab said, "It has entered
into a licensing agreement with Gilead Sciences, Inc under which Gilead has
extended non-exclusive rights to Strides to manufacture and distribute
Tenofovir Alafenamide (TAF), both as a single agent product and in combination
with other drugs."
Strides said that the license being granted to it extends to
"Strides will receive technology transfer from Gilead,
enabling Strides to manufacture low cost versions of TAF for developing countries,"
the company stated.
TAF is an investigational product in the US and have not yet
been determined safe and efficacious in humans.